Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies-Reference-Cited by-同舟云学术

Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies

Published:2018-03-02 Issue:6 Volume:97 Page:925-944
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Chen Min,Zhao Yongfeng,Xu Chuanxin,Wang Xian,Zhang Xianping,Mao Benyu

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3284-y/fulltext.html

Reference110 articles.

1. Vincent Rajkumar S (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999–1009. https://doi.org/10.1002/ajh.23810S

2. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21395

3. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20):3043–3051. https://doi.org/10.1182/blood-2014-07-552059

4. Röllig C, Knop S, Bornhäuser M (2015) Multiple myeloma. Lancet 385(9983):2197–2208. https://doi.org/10.1016/S0140-6736(14)60493-1

5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Siegel D, Crowley J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571. https://doi.org/10.1056/NEJM199911183412102

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Myeloma: A Review of the Literature and a Case Report Highlighting the Immunocompromised State of Myeloma Patients;World Journal of Oncology;2024-06

2. Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases;Therapeutic Advances in Infectious Disease;2024-01

3. INFECTION EVENTS IN MULTIPLE MYELOMA DURING THE EARLY PERIOD OF AUTOLOGOUS STEM CELL TRANSPLANTATION;J ISTANB FAC MED;2024

4. Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews;Annals of Hematology;2023-11-08

5. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era;Diseases;2023-09-18